Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Mehling

Vascular & Interventional Radiology Boulder, CO Medical Doctor

NPI 1639127574 CMS profile 751646

1100 Balsam Ave, Boulder, CO 80304

Open in the dashboard

General payments

$4,003

141 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Mehling of Boulder, CO is reported in the CMS Open Payments database as having received $4,003 across 141 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $967 32
2024 General $822 27
2023 General $773 27
2022 General $753 22
2021 General $94 4
2020 General $108 5
2019 General $487 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Mehling
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Jason Mehling were reported at $967. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Jason Mehling Vascular & Interventional Radiology median Middle half National median
2019 $487 $422 $125–$1,555 $163
2020 $108 $200 $68–$652 $114
2021 $94 $280 $99–$866 $132
2022 $753 $433 $137–$1,497 $149
2023 $773 $506 $152–$2,019 $160
2024 $822 $556 $175–$1,930 $164
2025 $967 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $595 19 payments
  2. Merck Sharp & Dohme Corporation $443 18 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $364 12 payments
  4. Eisai Inc. $314 11 payments
  5. Stryker Corporation $268 9 payments
  6. Inari Medical, Inc. $266 8 payments
  7. E.R. Squibb & Sons, L.L.C. $252 11 payments
  8. Exelixis Inc. $248 6 payments
  9. Seattle Genetics, Inc. $163 6 payments
  10. Penumbra, Inc. $125 2 payments
  11. Other $965 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,003 141 payments
Products named General payments · program years 2019–2025
  1. KEYTRUDA $373 14 payments
  2. Lenvima $314 11 payments
  3. CT THROMBECTOMY SYSTEM KIT $304 10 payments
  4. FLOWTRIEVER CATHETER, S $304 10 payments
  5. Stivarga $266 9 payments
  6. CABOMETYX $248 6 payments
  7. ENHERTU $235 7 payments
  8. Vitrakvi $216 7 payments
  9. Nubeqa $199 6 payments
  10. OPDIVO $185 8 payments
  11. Other $2,283 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 144 billing codes

Paid by Medicare

$103,252

Medicare's payments for the services billed

Medicare patients

1,510

Average age 75

Services billed

2,453

791 women, 719 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 49%
Diabetes 39%
Chronic kidney disease 38%
Heart failure 37%
Atrial fibrillation 35%
COPD 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • AstraZeneca Pharmaceuticals LP $140
$140 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $118
$118 — —
Lenvima
  • Eisai Inc. $87
$87 — —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $61
$61 — —
WELIREG
  • Merck Sharp & Dohme Corporation $52
$52 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

141 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record